HeraMED (ASX:HMD) PS Ratio: (As of Jul. 03, 2026)


What is HeraMED PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, HeraMED's share price is A$0.043. HeraMED's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00. Hence, HeraMED's PS Ratio for today is .

The historical rank and industry rank for HeraMED's PS Ratio or its related term are showing as below:

During the past 8 years, HeraMED's highest PS Ratio was 293.48. The lowest was 7.00. And the median was 66.03.

ASX:HMD's PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.94
* Ranked among companies with meaningful PS Ratio only.

HeraMED's Revenue per Sharefor the six months ended in Dec. 2025 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00.

During the past 12 months, the average Revenue per Share Growth Rate of HeraMED was -100.00% per year.

Back to Basics: PS Ratio


HeraMED  (ASX:HMD) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


HeraMED PS Ratio Related Terms


HeraMED PS Ratio Historical Data

* Premium members only.

The historical data trend for HeraMED's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeraMED PS Ratio Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial 234.78 122.28 11.74 20.00 0.00

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.74 0.00 0.00 0.00 0.00

ASX:HMD vs ABT, SYK, MDT: PS Ratio Comparison

For the Medical Devices subindustry, HeraMED's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeraMED PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's PS Ratio distribution charts can be found below:

* The bar in red indicates where HeraMED's PS Ratio falls into.



HeraMED PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

HeraMED's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.043/0
=

HeraMED's Share Price of today is A$0.043.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HeraMED's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


HeraMED Business Description

Other Exchanges 1I4:Germany
Address 117 Camberwell Road, Level 1 - Suite 1, Hawthorn East, Melbourne, VIC, AUS, 3123
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.